SOLICITATION NOTICE
B -- Enhancing the Comparability of World Health Organization (WHO) Study on Global Aging and Adult Health (SAGE) - solicitation
- Notice Date
- 9/6/2013
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211 - MSC 9559, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIDA-SSSA-2013-002-dch
- Archive Date
- 10/5/2013
- Point of Contact
- Debra C. Hawkins, Phone: 3014352178
- E-Mail Address
-
Debra.Hawkins@nih.gov
(Debra.Hawkins@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Combined synopsis-solicitation (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is HHS-NIH-NIDA-(SS/SA)-2013-002-dch and the solicitation is issued as a Request for Proposal (RFP). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures; FAR Subpart 13.5-Test Program for Certain Commercial Items; and FAR Part 12-Acquisition of Commercial Items, and is expected to exceed the simplified acquisition threshold. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2006-69, dated September 3, 2013. (iv) The associated NAICS code is 541990-All Other Professional, Scientific and Technical Services and the small business size standard is $14.0 Million. (v) Project Title: Enhancing the Comparability of World Health Organization (WHO) Study on Global Aging and Adult Health (SAGE) (vi) Background: Research findings have shown the power of cross-national comparisons to examine critical questions in aging ranging from sources of health differences among developed countries to the impact of early retirement from the labor force on cognition. Conducting cross-national research presents many opportunities for innovative work, but also presents complications, the most significant being comparability of data. If studies are conducted differently, instruments contain different survey items, or contain items that are constructed using different algorithms researchers cannot easily distinguish between actual differences in observed factors as opposed to artifacts of survey design or implementation. There is a need for internationally comparable datasets to permit cross-national investigation of aging populations. The NIA's Strategic Plan outlines the importance of studies on healthy aging, well-being and longevity, and places an emphasis on understanding how population aging and changes in social, economic, and demographic characteristics of cohorts reaching old age affect health and well-being in the United States and other countries. To this end, it explicitly calls for supporting "the development of internationally harmonized social and behavioral longitudinal data on aging to foster cross-national research." This project will support NIA priorities by funding harmonization activities in the ongoing World Health Organization Study on Global Aging and Adult Health (SAGE) project to make it more comparable to other NIA supported longitudinal aging studies. The WHO SAGE is a longitudinal study with nationally representative cohorts of persons aged 50 years and older in China, Ghana, India, Mexico, Russian Federation, South Africa, and large comparison samples of younger adults aged 18-49 years in each participating country. SAGE has included methodologies to improve cross-population comparability of health and well-being data to monitor and cross-nationally compare trends over time. WHO worked with local survey partners in each country, with three of the participating countries contributing supplemental funds to implement SAGE. A baseline cohort (Wave 0) was created during the 2002-2004 World Health Organization supported World Health Survey (WHS) based on nationally representative sampling frames. All samples were selected from nationally representative frames and sample sizes drawn based on feasibility and survey costs. The resulting sample sizes ranged from almost 39,000 in Mexico to 2,400 in South Africa. Face-to-face interviews were used to generate a dataset containing 63,445 adults aged 18 years and older, including 18,883 persons aged 50 years and older, in the six SAGE Wave 0 countries. Through NIA support for SAGE, the survey instrument included several domains covered in the HRS-style surveys supported by NIA including socio-demographics, health, risk factors, health system social capital, and interviewer observations. SAGE Wave 1 was fielded from 2007 to 2010 in the six SAGE countries to follow-up respondents from Wave 0 in four countries (Ghana, India, Mexico and Russia) and adds new respondents in all countries. Implementation of the full SAGE Wave 2 follow-up began in 2013 and included harmonized collection of dried blood spots comparable with the HRS and will complete in 2014. The total sample size is roughly 42,000 respondents across SAGE countries China (14,811), Ghana (5,108), India (11,230), Mexico (2,742), the Russian Federation (4,355) and South Africa (4,223). SAGE is ambitious and innovative, but grounded in validated techniques and practices. It is led by experienced investigators and a robust Advisory Group, thereby ensuring the use of the results, improving uptake of new techniques and sharing of methods with other data collection efforts and studies. The logistical and analytical plans include- archiving and analyzing data, maintaining the study cohort, and validating methodologies - which will provide data on ageing processes and the health of older persons while also strengthening future rounds of data collection. SAGE Wave 3 is set to enter the field in 2015, though the pre-field work and Wave 2 archiving will initiate in 2013. SAGE has strong linkages to HRS-type studies to support cross-national health research, particularly those in Mexico, China and India (MHAS, CHARLS and LASI, respectively) including an overlap in some sets of questions though SAGE will maintain a richer focus on health data. The proposed contract activities both build on existing contract activities for SAGE and advance NIA harmonization objectives through two primary tasks including archiving of de-identified data to support public-use of the data by the research community and the alignment of approaches for collection of saliva following protocols from the NIA-funded US Health and Retirement Study. Specifically, Task 1 will archive dried blood spot (DBS) assays collected during SAGE Wave 1 (under the current NIA contract with SAGE) and make the data available (along with the other waves of SAGE data) for download from the WHO SAGE website (http://www.who.int/healthinfo/sage/en/). The assays of dried blood spot samples from SAGE include Hb, HbA1c, hsCRP, and EBV - similar assays to those conducted in other NIA-funded longitudinal aging studies. These data will be systematically documented with all metadata and archived along with the SAGE wave 1 interview data. Task 2 will support the collection of saliva using the commercially available Oragene kit for SAGE respondents - the same approach used by the US Health and Retirement Study. HRS and ELSA currently collect DNA samples and the HRS has already carried out extensive GWAS studies. Collecting DNA samples in SAGE is extremely valuable since SAGE collects data on populations that are ethnically different but using several comparable measures. Reproducibility of results across these samples would greatly increase the confidence in the results obtained from HRS, ELSA and other studies that collect saliva in the future, such as SHARE. This will ensure that researchers have access to comparable SAGE data to conduct cross-national analyses as well as within country analyses using SAGE. These Tasks follow from current contract activities that support collection of data, such as biomarkers comparable with other NIA-supported longitudinal aging studies, for SAGE Wave 2. Scope of Work: This project would continue NIA's support of ongoing work to improve the comparability of data on older populations around the world. It has two main tasks, all of them increasing the cross-national comparability within SAGE and with other NIA longitudinal aging data studies around the world modeled after the Health and Retirement Study. Task 1 will produce public-use de-identified dried blood spot assay metadata and supporting documentation. The data will provide researchers with objective measures of health comparable to assay data collected by other longitudinal aging studies such as the HRS, CHARLS, ELSA, SHARE and LASI. Task 2 will implement the collection of saliva using approaches similar to those employed by the Health and Retirement Study using Oragene kits during a face-to-face interview to ensure protocol compliance. A subsample will be collected during the ongoing fieldwork for Wave 2 to ensure sample quality. Saliva will then be collected in face-to-face interviews conducted for Wave 3 SAGE in China, India, Mexico and Russia for the complete sample of 32,000 respondents. The DNA will isolated using Prep-IT kits and stored. Specifically, Task 2 covers the costs of adding saliva collection to the face-to-face interviews of SAGE Wave 2 and 3 supported through other sources. Together, these tasks improve the comparability of SAGE to the HRS family of longitudinal aging studies supported by the NIA. Specific Requirements: This project consists of two (2) non-severable tasks as outlined below. Task 1: Archiving SAGE DBS Assay data for public-use by the research community An ongoing contract with NIA covers the collection of SAGE data. This Task builds on previous work by making previously collected objective health data comparable to other HRS family studies available to the research community. Specifically, several of the HRS family of studies collect blood and conducts assays for diabetes (Hb, HbA1c), inflammation (hsCRP), Epstein-Barr virus (EBV) and HIV. SAGE has collected blood from study participants and conducted identical assays. Task 1 supports the production of the assay data into de-identified survey data with supporting documentation for researchers that can be used to analyze SAGE countries and compare objective health across HRS-like studies due to the harmonized measurement. The data will be made publicly available to the research community by SAGE (September 2013-July 2014). Subtask 1.1: Prepare Assay Data for Archiving This Subtask will support work by the SAGE team to clean and collate results from DBS assays for archiving. This requires the survey team to conduct case-by-case production of assay metadata for all assays conducted (diabetes (Hb, HbA1c), inflammation (hsCRP), Epstein-Barr virus (EBV) and HIV) into a respondent-level format for matching to the SAGE survey data file. The SAGE team will document the metadata structure to provide guidance to users of the data. Subtask 1.2: Make Assay Data and Documentation Available for Public Use Once the objective health data from dried blood spot assays for diabetes (Hb, HbA1c), inflammation (hsCRP), Epstein-Barr virus (EBV) and HIV have been produced and appropriately documented, the SAGE team will electronically archive the data. The archived data will be in a respondent-level format as per the other publicly-available SAGE data. The de-identified archived data will be made available to researchers for public-use through the SAGE website. Documentation describing the archived objective health data from DBS assays will also be made available to researchers via the SAGE website. All archived data will be subject to the same conditions of use applied to other SAGE data. Task 2: Collection of Saliva Samples in SAGE Linking DNA to a rich collection of comparable phenotypes opens up new research opportunities using the HRS family of studies. Task 2 supports the collection of saliva to support such cross-national research using methods utilized by the Health and Retirement Study. Specifically, the task will support the addition of saliva collection using Oragene kits during face-to-face interviews for SAGE 2 and SAGE 3. The initial saliva collection will be added to the ongoing SAGE 2 field period and will be for a subsample of respondents from each SAGE country to ensure the protocol is collecting sample of adequate quality for genome-wide association studies (GWAS). The SAGE 3 collection will include saliva collection for all respondents from China, India, Mexico and Russia, about 32,000 total respondents. The SAGE team will use Prep-IT kits to isolate DNA and store the samples for future use in GWAS (December 2013-July 2015). Subtask 2.1: Saliva Collection in Wave 2 Subsample Using HRS Methods This Subtask will support the collection of saliva using methods comparable to the HRS during the ongoing SAGE Wave 2 face-to-face interviews for a subsample of 100 respondents per SAGE country (i.e., China, Ghana, India, Mexico, the Russian Federation and South Africa) for a total of 600 respondents. This task does not support the cost of face-to-face interviews - it supports the materials required to add saliva collection to the ongoing interview. To remain comparable to HRS, SAGE will utilize Oragene kits to collect samples. Subtask 2.2: Produce Preliminary Data from Wave 2 Saliva Collection This Subtask will both store collected saliva from the Wave 2 subsample collection and provide information on the quality of the data collection. First, all saliva collected will from the Wave 2 six country subsamples will have DNA isolated and extracted using PrepIT kits. The SAGE team will conduct a preliminary GWAS analysis using the subsample data collected to confirm the quality of the samples and provide a brief report of results from the subsample saliva collection including response rates and measures of sample quality by country. Samples collected will be appropriately stored by the SAGE team for future research use. Subtask 2.3: Wave 3 Saliva Collection in China, India, Mexico and Russia using HRS Methods This Subtask will support the collection of saliva using methods comparable to the HRS during the SAGE Wave 3 face-to-face interviews for all SAGE respondents in China, India, Mexico, and Russia (roughly 32,000 respondents). The SAGE wave 3 interview field period is scheduled for spring of 2015 and will be informed by the subsample saliva collection and meta data from the Wave 2 SAGE saliva collection. This task does not support the cost of face-to-face interviews - it supports the materials required to add saliva collection to the SAGE Wave 3 interview. To remain comparable to HRS, SAGE will utilize Oragene kits to collect samples. Subtask 2.4: Produce Preliminary Data from Wave 3 Saliva Collection This Subtask will both store collected saliva from the Wave 3 collection and provide information on the quality of the data collection. First, all saliva collected will from the Wave 3 in in China, India, Mexico, and Russia (roughly 32,000 respondents) will have DNA isolated and extracted using PrepIT kits. Samples collected will be appropriately stored by the SAGE team for future research use in GWAS. The SAGE team will provide a brief report of results from the saliva collection including response rates and measures of sample quality by country. Deliverable / Delivery Schedule: DELIVERABLES AND DELIVERY SCHEDULE Description Period of Performance / Due Date Task 1: Archiving SAGE DBS Assay Data for Public Use by the Research Community September 2013 - July 2014 Subtask 1.1: Prepare Assay Data for Archiving Milestone 1: Complete cleaning and collating of assay results and relevant metadata June 2014 Subtask 1.2: Make Assay Data and Documentation Available for Public Use. Milestone 2: Assay metadata and documentation available for use via SAGE July 2014 Task 2: Collection of saliva samples for extracting DNA December 2013 - July 2015 Subtask 2.1: Saliva Collection in Wave 2 Subsample Using HRS Methods Milestone 3: Complete saliva collection for 100 respondents per country using Oragene kits March 2014 Subtask 2.2: Produce Preliminary Data from Wave 2 Saliva Collection Milestone 4: Isolate DNA, storage and preliminary GWAS analysis of saliva collection for Wave 2 subsample May 2014 Subtask 2.3: Saliva collection in Wave 3 for China, India, Mexico and Russia using HRS methods Milestone 5: Complete saliva collection using Oragene kits for respondents in China, India, Mexico, and Russia for a total of 32,000 respondents July 2015 Subtask 2.4: Produce Preliminary data from Wave 3 saliva collection. Milestone 6: Isolate DNA, storage and report on saliva collection for Wave 3 sample July 2015 (vii) The place of performance is at the contractor's location during the period of performance as specified in the delivery schedule. (viii) The provision of FAR clause 52.212-1, Instructions to Offerors - Commercial Items (July 2013), applies to this acquisition. (ix) The Addendum of FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. (a) Technical Proposal Instructions and Format 1. The technical proposal is the most important item in the evaluation of the contractor's capability to perform the desired services. Therefore, the proposal must present sufficient information to reflect a thorough understanding of the work requirements and a detailed technical approach for achieving project objectives as set forth in the statement of work. 2. The technical proposal may NOT contain any references to price-cost. However, resource information, such as data concerning proposed other direct costs, must be contained in the technical proposal so that contractor's understanding of the scope of work may be evaluated. 3. All aspects of a proposal are subject to discussion, including price, technical approach, and terms and conditions. At the completion of discussions, the contractor must ensure its technical plan and price-cost proposal reflect the mutual understandings of the requirement and, if requested, submit a revised technical plan and price-cost proposal. The technical plan should consist of the contractor's intent and approach to the requirements, any considerations that should be made by the Government, as well as any additional information that expresses the contractor's position above competitors for this effort. 4. The technical proposal must be submitted in Microsoft Word or searchable PDF format in a font size of 11 or 12 point and font type of Arial or Times New Romans. Margins must be 1-inch wide (top, bottom, left, and right). The technical proposal must not exceed 20-pages in length and the pages must be sequentially numbered regardless of the section or part (e.g., 1 of 25, 2 of 25, 3 of 25, etc.,) and must contain a header or footer to include the name of the contractor and the solicitation number. Pages in excess of the specified page limit will not be considered or evaluated. Resumes must not exceed 2 pages in length and are not counted in the page limit. (b) Price-Cost Proposal Instructions 1. The price-cost proposal is submitted separately from the technical proposal and shall be submitted in the below format, for each Task required to perform the services as specified the statement of work. 2. A fixed-price (FP) proposal is requested. The FP proposal shall be based on the prices in the schedule contract and shall consider the mix of labor categories and level of effort required to perform the services described in the statement of work. The price-cost proposal is submitted separately from the technical proposal for each task/sub-task as specified in the statement of work and for each year / partial year of the period of performance, and option periods, including a summary of the costs for the entire period of performance. 3. The cost-price proposal must list all direct costs associated in the performance each task, i.e., labor, consultants, travel, transportation, and training, etc. Any travel costs must be proposed at the rates provided in the federal travel or joint travel regulations. 4. The cost-price proposal must include a complete explanation detailing the rationale for each cost. In addition, the rationale should be sufficient enough to determine that the all costs are fair and reasonable. The FP price-cost proposal must be submitted in the below format. Cost-Price Proposal Task Area Unit Price Total Fixed Price Task 1, Subtask 1.1 Task 1, Subtask 1.2 Total Task 1 Task 2, Subtask 2.1 Task 2, Subtask 2.2 Task 2, Subtask 2.3 Task 2, Subtask 2.4 Total Subtask 2 Total Fixed Price (x) The provision of FAR clause 52.212-2, Evaluation - Commercial Items (January 1999), applies to this acquisition. (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: No. Criterion Description Total Possible Points 1. Understanding the Statement of Work The proposal should address each requested task in sufficient detail to demonstrate a clear understanding of the statement of work. The offeror should provide evidence of sufficient planning to show that work will be accomplished as required and on schedule. a. Proposal demonstrates an understanding of the requirements and goals set forth in the Statement of Work (10) b. Proposal addresses each requirement in the Statement of Work (20) c. Proposal shows plan/timeline to accomplish tasks in a reasonable timeframe (5) d. Proposal includes appropriate personnel and effort to carry out all tasks (10) 45 2. Access to the Study on Global Ageing and Adult Health (SAGE) study sample frame The offeror must demonstrate in its proposal how it will obtain access to the existing SAGE sample frame and the ability to re-contact SAGE respondents. NOTE: The purpose of this requirement is to harmonize data within the ongoing SAGE panel with the US Health and Retirement Study family of international studies to support cross-national research on aging. While similar data could be collected contemporaneously on a new sample, such an endeavor would lack the historic harmonized panel of data available in the SAGE sample. The existence of three prior waves of data makes harmonization of SAGE a high priority to NIA. 5 3. Past Performance/Relevant Experience The offeror must demonstrate its relevant experience and performance conducting the tasks requested under the Statement of Work. This includes experience conducting longitudinal aging studies, biomarker and physical performance measures, and managing a multi-country study. a. Experience of study leadership (20) - supply a resume for study leadership that includes education, experience, background, accomplishments, and other pertinent information. b. Provide information of survey experience of project team conducting multi-country longitudinal aging studies (30) - this should include explanations of experience conducting surveys with face-to-face interviews, biomarker and performance measure collection, and relevant training to conduct surveys harmonized to the Health and Retirement Study family of international studies. 50 Total Possible Score 100 (b) Options. The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement. The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced. Evaluation of options shall not obligate the Government to exercise the option(s). (c) A written notice of award or acceptance of an offer mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (xi) The Addendum to FAR clause 52.212-2, Evaluation - Commercial Items (January 1999), applies to this acquisition. (a) GENERAL. Selection of an offeror for contract award will be based on an evaluation of proposals against the above factors. Although technical factors are of paramount consideration in the award of the contract, past performance, and cost-price are also important to the overall contract award decision. All evaluation factors other than cost or price, when combined, are approximately equal to cost-price. The Government intends to make an award(s) to that offeror whose proposal provides the best overall value to the Government. (b) The evaluation will be based on the demonstrated capabilities of the prospective Contractors in relation to the needs of the project as set forth in the solicitation. The merits of each proposal will be evaluated carefully. Each proposal must document the feasibility of successful implementation of the requirements of the solicitation. Offerors must submit information sufficient to evaluate their proposals based on the detailed factors listed below. (c) COST/PRICE EVALUATION. Offeror(s) cost/price proposal will be evaluated for reasonableness. For a price to be reasonable, it must represent a price to the government that a prudent person would pay when consideration is given to prices in the market. Normally, price reasonableness is established through adequate price competition, but may also be determined through cost and price analysis techniques as described in FAR 15.404. (xii) The Offeror must include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications - Commercial Items (August 2013), with its offer. The FAR clause is located at http://www.acquisition.gov/far/. (xiii) FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items (July 2013), applies to this acquisition. (xiv) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items (September 2013), applies to this acquisition. Specifically, the following clauses cited in FAR clause 52.212-5 are applicable to this acquisition: (a) 52.222-50, Combating Trafficking in Persons (FEB 2009) (22 U.S.C. 7104(g)), Alternate I (AUG 2007) of 52.222-50 (22 U.S.C. 7104(g)) (b) 52.204‐10, Reporting Executive Compensation and First‐Tier Subcontract Awards (AUG 2012) (Pub.L. 109‐282)(31 U.S.C. 6101 note). (c) 52.209-7, Information Regarding Responsibility Matters (Jul 2013) (d) 52.209-9, Updates of Publicly Available Information Regarding Responsibility Matters (JULY 2013) (41 U.S.C. 2313) (e) 52.219-14, Limitations on Subcontracting (NOV 2011) (15 U.S.C. 637(a)(14)) (f) 52.222-21, Prohibition of Segregated Facilities (FEB 1999) (g) 52.222-26, Equal Opportunity (MAR 2007) (E.O. 11246) (h) 52.222-35, Equal Opportunity for Veterans (SEP 2010) (38 U.S.C. 4212) (i) 52.222-36, Affirmative Action for Workers with Disabilities (OCT 2010) (29 U.S.C. 793) (j) 52.222-37, Employment Reports on Veterans (SEP 2010) (38 U.S.C. 4212) (k) 52.223-18, Encouraging Contractor Policies to Ban Text Messaging while Driving (AUG 2011) (l) 52.225-13, Restrictions on Certain Foreign Purchases (JUN 2008) (E.O.'s, proclamations, and statutes administered by the Office of Foreign Assets Control of the Department of the Treasury) (m) 52.222-50, Combating Trafficking in Persons (FEB 2009) (22 U.S.C. 7104(g)) Alternate I (AUG 2007) of 52.222-50 (22 U.S.C. 7104(g)). (xv) There are no additional contract requirement(s) or terms and conditions determined by the contracting officer to be necessary for this acquisition and consistent with customary commercial practices. (xvi) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xvii) Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: cost-price proposal, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." All responses must be received by September 20, 2013, 4:30 p.m. eastern standard time and must reference number HHS-NIH-NIDA-(SS/SA)-2013-002-dch. Responses may be submitted electronically to Debra.Hawkins@nih.gov or by U.S. mail to the National Institute of Drug Abuse (NIDA), Station Support / Simplified Acquisition Branch (SS/SA), 31 Center Drive, Building 31, Room 1B59, Bethesda, Maryland 20892, Attention: Debra C. Hawkins. Fax responses will not be accepted. (xviii) Contact Debra Hawkins at 301-594-2178 for information regarding the solicitation.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/HHS-NIH-NIDA-SSSA-2013-002-dch/listing.html)
- Place of Performance
- Address: At contractor's site, to be determined., United States
- Record
- SN03177478-W 20130908/130906235551-23d1a9ad28bdd18aaa64eb65738f460f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |